Anti-CD19/CD8 bispecific T cell engager for the potential treatment of B cell malignancies.

• Administration of blinatumomab was accompanied by several adverse effects. • The αCD8/CD19 BiTE was produced to boost Blinatumomab effectiveness. • The αCD8/CD19 induced cytotoxic activity against CD19+ cancer cells. The administration of blinatumomab was accompanied by several adverse effects, including activation of regulatory T -cells and cytokine storm. The objective of this study was to produce and evaluate a novel αCD8/CD19 BiTE (αCD8/CD19) with the potency to directly target CD8+ T -cells. In-silico studies were utilized for determining proper folding, receptor binding, and structural stability of αCD8/CD19 protein. Western blotting and indirect surface staining were used to evaluate the size accuracy and binding potency of the purified protein. Functionality was assessed for granzyme B production, cytotoxicity, and proliferation. The αCD8/CD19 recombinant protein was produced in the CHO-K1 cell line with a final concentration of 1.94 mg/l. The αCD8/CD19 bound to CD8+ and CD19+ cell lines and induced significant granzyme B production, cytotoxic activity and proliferation potential in the presence of IL-2 and tumor target cells. The maximum CD8+ T -cell biological activity was observed on the 10th day with 10:1 effector-to-target ratio. [ABSTRACT FROM AUTHOR]